NCT05278351View on ClinicalTrials.gov

Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC

PHASE2RecruitingINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

July 13, 2022

Primary Completion Date

April 1, 2024

Study Completion Date

December 1, 2025

Conditions
Colorectal Neoplasms Malignant
Interventions
DRUG

Tislelizumab Combined With Cetuximab and Irinotecan

Tislelizumab (an anti-PD-1 monoclonal antibody) Cetuximab (monoclonal antibody against EGFR) Irinotecan

DRUG

Third-line regimens

Trifluridinetipiracil or Regorafenib or Fruquintinib

Trial Locations (1)

200032

RECRUITING

Shanghai Zhongshan Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Zhongshan Hospital

OTHER